Selective prescribing of third generation oral contraceptives (OCs)

Contraception

Volumn 54, Issue 1, 1996, Pages 55-56

  Jamin, Christian ^a,b   De Mouzon, Jacques ^b  

^a Hôpital de Bicêtre ^*  (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

second and third generation OCs; venous thromboembolism

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; DRUG CLASSIFICATION; FRANCE; HUMAN; PHYSICIAN ATTITUDE; PRESCRIPTION; THROMBOEMBOLISM;

EID: 0030200956     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(96)00120-5     Document Type: Article

References (4)

1. 1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-81.
2. 2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-88.
3. 3. H Jick, SS Jick, V Gurewich, MW Myers, C Vasilakis. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-92.
4. 4. WO Spitzer, MA Lewis, LAJ Heinemann, M Thorogood, KD MacRae on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-7.